In the current study, we aim to evaluate the significance of serum Adiponectin level and insulin resistance among patients with chronic liver disease and hepatocellular carcinoma and to explore the relation of Adiponectin and insulin resistance to the metabolic profile in these patients. This evidence concerns the gene ADIPOQ and hepatocellular carcinoma.